CureVac Takes Another Shot At mRNA Vaccines, Expands Cancer Work
Wants To Compete With Neighbors BioNTech
Its first COVID-19 vaccine failed last year, but fueled by payments from the EU, Germany and GSK, CureVac is trying again with two further versions of its mRNA platform.
